secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001384101-24-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes
-----------------------------------------------------------------------------

- Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).
- Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.
- Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).
- Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/0001384101-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/vcyt-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001384101-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer